Kaitanni (cadonilimab)

P2, N=78, Recruiting, Akeso | Not yet recruiting --> Recruiting | N=60 --> 78 | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

Unfortunately, the patient progressed rapidly during maintenance therapy when cadonilimab was replaced by sintilimab, the monoclonal antibody against PD-1, indicating the more powerful anti-tumor activity of dual blockade immunotherapy. To conclude, cadonilimab offers a promising and effective therapeutic approach for R/M CC. Notably, HER-2 is also expected to be a new reference target for cadonilimab therapy.

P2, N=23, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Eligible patients will be registered and receive three cycles of oxaliplatin and S-1 (SOX) regimen in combination with cadonilimab...The results of the study may provide more evidence for neoadjuvant immunotherapy combined with chemotherapy in locally advanced G/GOJ adenocarcinoma. ClinicalTrials.gov, NCT05948449.

P2, N=30, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting

P=N/A, N=20, Not yet recruiting, First Affiliated Hospital of Ningbo University

P=N/A, N=20, Enrolling by invitation, Hubei Cancer Hospital

P2, N=51, Recruiting, Hubei Cancer Hospital | Not yet recruiting --> Recruiting

P1, N=66, Active, not recruiting, Akesobio Australia Pty Ltd | Recruiting --> Active, not recruiting | N=143 --> 66 | Trial primary completion date: Jan 2025 --> Oct 2024

Neoadjuvant cadonilimab plus FLOT chemotherapy treatment exhibits promising efficacy with manageable toxicities in locally advanced G/GEJ adenocarcinoma, providing preliminary evidence for further investigation.

P=N/A, N=75, Not yet recruiting, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine; Shanghai First Maternity and Infant Hospital, Tongji University Sc

P=N/A, N=30, Not yet recruiting, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi

P2, N=172, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

P2, N=58, Not yet recruiting, Xuancheng People's Hospital; Xuancheng People's Hospital of Anhui Province

P2, N=54, Not yet recruiting, The second hospital of Lanzhou University; The second hospital of Lanzhou University

P2, N=51, Not yet recruiting, Hebei Medical University Fourth Hospital

P2, N=14, Completed, Akeso | Not yet recruiting --> Completed | N=30 --> 14 | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Mar 2023 --> Sep 2024

P3, N=84, Active, not recruiting, Sun Yat-sen University

P2, N=25, Not yet recruiting, Wuhan Union Hospital, China

P1/2, N=90, Recruiting, Zhejiang Cancer Hospital

This report marks the first documented instance of an oral adverse effect associated with Cadonilimab use. It underscores that administration of this agent may lead to significant lichenoid lesions and erosions within the oral cavity-an issue warranting increased vigilance from both oncologists and stomatologists.

P1/2, N=110, Not yet recruiting, Akeso

P2, N=36, Recruiting, Tongji Hospital | Trial completion date: Jun 2026 --> Jun 2027

TRAEs of grade 3 or higher occurred in 51.7 % of patients, with no grade 4 TRAEs observed. This study demonstrated the efficacy and safety of this combination, potentially improving outcomes as a first-line therapy, and offering a novel therapeutic approach for advanced HCC.

In this heavily pretreated cohort of advanced NSCLC patients, cadonilimab-based regimens showed moderate antitumor efficacy with a generally tolerable and manageable safety profile. However, more evidence is needed to support the administration of cadonilimab in NSCLC patients refractory to previous anti-PD-1/PD-L1 therapy.

P2, N=70, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China

P3, N=560, Not yet recruiting, Akeso

P2, N=33, Recruiting, Chongqing University Cancer Hospital | Trial primary completion date: Jun 2024 --> Dec 2024

P=N/A, N=20, Recruiting, Fujian Provincial Hospital | Not yet recruiting --> Recruiting

P2, N=50, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Sep 2024

P=N/A, N=60, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P=N/A, N=46, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P=N/A, N=20, Not yet recruiting, Hubei Cancer Hospital; Hubei Cancer Hospital

P3, N=469, Recruiting, Zhongda Hospital Southeast University; Zhongda Hospital Southeast University

P2, N=32, Not yet recruiting, Yunnan Cancer Hospital; Yunnan Cancer Hospital

P2, N=30, Recruiting, Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University

P2, N=39, Not yet recruiting, The First Hospital of Lanzhou University; The First Hospital of Lanzhou University

P2, N=52, Not yet recruiting, the First affiliated hospital of Soochow university; the First affiliated hospital of Soochow university

P2, N=30, Recruiting, Shandong Cancer Hospital Affiliated to Shandong First Medical University; Shandong Cancer Hospital Affiliated to Shandong First Medical University

P=N/A, N=200, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2026 --> Dec 2024

P2, N=50, Recruiting, Shanghai Zhongshan Hospital

P1/2, N=294, Not yet recruiting, Akeso